Recommended Medications for Severe Anxiety
SSRIs and SNRIs are the first-line pharmacological treatments for severe anxiety disorders due to their established efficacy, favorable safety profiles, and low risk of dependence. 1, 2, 3
First-Line Medications
Selective Serotonin Reuptake Inhibitors (SSRIs)
- SSRIs demonstrate high treatment response rates with number needed to treat (NNT) = 4.70 and dropout rates similar to placebo, indicating good efficacy and tolerability 1
- Specific SSRIs with strong evidence for anxiety disorders include:
- Sertraline - well-tolerated with low potential for pharmacokinetic drug interactions 4
- Paroxetine - effective but associated with higher risk of discontinuation syndrome 1
- Fluoxetine - longer half-life allowing for less frequent dosing 1
- Escitalopram/Citalopram - may have least effect on CYP450 isoenzymes and lower propensity for drug interactions 1
- Important considerations with SSRIs:
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- SNRIs show similar efficacy to SSRIs with NNT = 4.94 and comparable safety profile 1
- Venlafaxine has the most robust evidence among SNRIs for anxiety disorders 1, 5
- SNRIs may offer potential clinical advantages over SSRIs in some patients with anxiety disorders 5
Second-Line Medications
When SSRIs and SNRIs fail or are not tolerated, consider:
Benzodiazepines
- Recommended for rapid anxiety relief in short-term use 2, 6
- Alprazolam is FDA-approved for generalized anxiety disorder and panic disorder 6
- Caution: Not recommended for routine or long-term use due to risk of dependence and tolerance 2, 3
Anticonvulsants
- Pregabalin has demonstrated efficacy as a second-line treatment 2
- Gabapentin may be beneficial, particularly in patients with comorbid pain conditions 2
Other Options
- Buspirone - alternative for generalized anxiety disorder 3, 7
- Tricyclic antidepressants (TCAs) - effective but less well-tolerated than SSRIs/SNRIs 3, 7
- Mirtazapine, trazodone, nefazodone - considered second-line based on open-label studies 8
Treatment Approach
Medication Initiation and Titration
- Start with low doses and increase gradually:
Combination Therapy
- Consider combination of medication with Cognitive Behavioral Therapy (CBT) for optimal outcomes 2
- For children and adolescents, combination treatment (CBT plus SSRI) is suggested over monotherapy 1
Important Precautions
- Monitor for initial worsening of anxiety symptoms when starting SSRIs 1
- Avoid paroxetine in patients at risk for suicidal ideation 1
- Avoid citalopram doses exceeding 40mg/day due to risk of QT prolongation 1
- Avoid concomitant use of MAOIs with SSRIs due to risk of serotonin syndrome 1
- After achieving remission, continue medications for 6-12 months to prevent relapse 3
Special Considerations
- For rapid symptom relief while waiting for SSRIs/SNRIs to take effect, short-term benzodiazepine use may be considered 7
- In treatment-resistant cases, augmentation with atypical antipsychotics may be beneficial 8
- Regular monitoring by a physician with expertise in anxiety disorders is essential for evaluating treatment response 2